Publications

2012

Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, et al. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012;7(6):e38881.
Mian M, Scandurra M, Chigrinova E, Shen Y, Inghirami G, Greiner TC, et al. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. Ann Oncol. 2012;23(3):729-735.
Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, et al. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. Curr Urol Rep. 2012;13(2):122-35.
Huang X, Di Liberto M, Jayabalan D, Liang J, Ely S, Bretz J, et al. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4. Blood. 2012;120(5):1095-106.
Zhang T, DeSimone RA, Jiao X, F Rohlf J, Zhu W, Gong QQ, et al. Host genes related to paneth cells and xenobiotic metabolism are associated with shifts in human ileum-associated microbial composition. PLoS One. 2012;7(6):e30044.
Kim J, Kim W-, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle. 2012;11(6):1123-30.
Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, et al. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget. 2012;3(6):651-63.
Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1497-509.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700